PreveCeutical Medical Inc. (PREV.CN)
CAD 0.03
(0.0%)
CAD 0.03
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -963.12 Thousand CAD | 12.26% |
| 2022 | -1.09 Million CAD | -22.25% |
| 2021 | -897.85 Thousand CAD | 58.05% |
| 2020 | -2.14 Million CAD | 38.98% |
| 2019 | -3.5 Million CAD | -50146.84% |
| 2018 | -6980.22 CAD | 99.84% |
| 2017 | -4.49 Million CAD | -66.13% |
| 2016 | -2.7 Million CAD | -4230.9% |
| 2015 | -62.45 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -142.11 Thousand CAD | 59.71% |
| 2024 Q2 | -275.54 Thousand CAD | -93.89% |
| 2023 Q4 | -352.7 Thousand CAD | -130.34% |
| 2023 Q3 | -153.12 Thousand CAD | 5.81% |
| 2023 Q1 | -294.74 Thousand CAD | -10.23% |
| 2023 FY | -963.12 Thousand CAD | 12.26% |
| 2023 Q2 | -162.56 Thousand CAD | 44.85% |
| 2022 Q1 | -161.06 Thousand CAD | 44.34% |
| 2022 Q3 | -495.4 Thousand CAD | -185.06% |
| 2022 Q4 | -267.38 Thousand CAD | 46.03% |
| 2022 Q2 | -173.78 Thousand CAD | -7.9% |
| 2022 FY | -1.09 Million CAD | -22.25% |
| 2021 FY | -897.85 Thousand CAD | 58.05% |
| 2021 Q1 | -377.37 Thousand CAD | 75.51% |
| 2021 Q4 | -289.36 Thousand CAD | -431.83% |
| 2021 Q3 | 87.2 Thousand CAD | 127.4% |
| 2021 Q2 | -318.31 Thousand CAD | 15.65% |
| 2020 Q3 | 420.82 Thousand CAD | 156.85% |
| 2020 FY | -2.14 Million CAD | 38.98% |
| 2020 Q1 | -279.75 Thousand CAD | -55.35% |
| 2020 Q2 | -740.18 Thousand CAD | -164.58% |
| 2020 Q4 | -1.54 Million CAD | -466.21% |
| 2019 Q3 | -902.7 Thousand CAD | 34.01% |
| 2019 Q2 | -1.36 Million CAD | -29.45% |
| 2019 Q4 | -180.08 Thousand CAD | 80.05% |
| 2019 Q1 | -1.05 Million CAD | -117.96% |
| 2019 FY | -3.5 Million CAD | -50146.84% |
| 2018 Q1 | -1.33 Million CAD | 42.72% |
| 2018 FY | -6980.22 CAD | 99.84% |
| 2018 Q4 | 5.88 Million CAD | 335.7% |
| 2018 Q3 | -2.49 Million CAD | -19.65% |
| 2018 Q2 | -2.08 Million CAD | -55.71% |
| 2017 Q1 | -94.55 Thousand CAD | 20.86% |
| 2017 Q2 | -668.42 Thousand CAD | -606.91% |
| 2017 Q3 | -1.12 Million CAD | -68.31% |
| 2017 FY | -4.49 Million CAD | -66.13% |
| 2017 Q4 | -2.33 Million CAD | -107.93% |
| 2016 Q3 | -106.02 Thousand CAD | -297.5% |
| 2016 Q1 | -32.29 Thousand CAD | -90.42% |
| 2016 Q2 | -26.67 Thousand CAD | 17.41% |
| 2016 FY | -2.7 Million CAD | -4230.9% |
| 2016 Q4 | -119.47 Thousand CAD | -12.69% |
| 2015 Q4 | -16.96 Thousand CAD | -895.36% |
| 2015 FY | -62.45 Thousand CAD | 0.0% |
| 2015 Q3 | -1704.00 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -5.01 Million CAD | 80.807% |
| Asep Medical Holdings Inc | -7.72 Million CAD | 87.526% |
| BetterLife Pharma Inc. | -3.24 Million CAD | 70.276% |
| BioVaxys Technology Corp. | -2.4 Million CAD | 59.913% |
| ChitogenX Inc. | -2.83 Million CAD | 65.967% |
| Rapid Dose Therapeutics Corp. | -3.73 Million CAD | 74.24% |
| Defence Therapeutics Inc. | -12.65 Million CAD | 92.39% |
| Entheon Biomedical Corp. | -313.99 Thousand CAD | -206.735% |
| Gemina Laboratories Ltd. | -5.08 Million CAD | 81.063% |
| Glow Lifetech Corp. | -1.64 Million CAD | 41.37% |
| Lexston Life Sciences Corp. | -674.71 Thousand CAD | -42.745% |
| Pharmala Biotech Holdings Inc. | -762.95 Thousand CAD | -26.237% |
| Doseology Sciences Inc. | -377.63 Thousand CAD | -155.042% |
| MYND Life Sciences Inc. | -1.8 Million CAD | 46.723% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | 19.893% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 68.361% |
| Telescope Innovations Corp. | -5.76 Million CAD | 83.299% |